Laboratory Epsylon, EA 4556, Montpellier, France; University Department of Adult Psychiatry, CHRU Montpellier, Montpellier, France.
Schizophr Res. 2013 Mar;144(1-3):118-21. doi: 10.1016/j.schres.2012.12.011. Epub 2013 Jan 10.
The processes underlying the ability to make decisions about recommended treatments remain poorly understood in schizophrenia. The aim of this study was to explore the relationships between capacity to consent to medication and cognitive biases in 60 schizophrenia patients. Main measures included the MacArthur Competence Assessment tool for Treatment (MacCAT-T) and the Beck Cognitive Insight Scale (BCIS). After Bonferroni's correction for multiple correlations, the Self-Reflectiveness dimension of the BCIS was significantly associated with the dimension "Reasoning" of the MacCAT-T. Cognitive therapy, by enhancing patients' Self-Reflectiveness and considering alternative explanations, could lead to better capacity to consent to treatment in schizophrenia.
在精神分裂症中，人们对做出推荐治疗决策的能力的潜在机制仍知之甚少。本研究旨在探讨 60 名精神分裂症患者的同意用药能力与认知偏差之间的关系。主要测量指标包括麦克阿瑟治疗能力评估工具（MacCAT-T）和贝克认知洞察力量表（BCIS）。经多重相关的 Bonferroni 校正后，BCIS 的自我反省维度与 MacCAT-T 的“推理”维度显著相关。认知疗法通过提高患者的自我反省能力并考虑替代解释，可能会导致精神分裂症患者更好地同意治疗。
